Mathematical model to predict the need for neodymium:YAG capsulotomy based on posterior capsule opacification rate

被引:10
作者
Clark, DS [1 ]
Munsell, MF [1 ]
Emery, JM [1 ]
机构
[1] Medarex Inc, Annandale, NJ 08801 USA
关键词
D O I
10.1016/S0886-3350(98)80353-2
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To evaluate a model to project the estimated time required before patients primary phacoemulsification require neodymium:YAG (Nd:YAG) laser capsulotomy. Setting: Eleven private practices in the United States. Methods: Projections of time to capsulotomy were based on assessment of the early development of posterior capsule opacification (PCO) over lime. The PCO data I were collected during a clinical study to evaluate MDX-RA, an investigational immunotoxin designed to limit epithelial cell growth, preventing postsurgical PCO. From the PCO data, the estimated time to Nd:YAG capsulotomy in a placebo-treated group was compared with the actual time to capsulotomy in a cohort of patients from general practice who had had phacoemulsification. Results: By 6 months, the mean Opacification index in the MDX-RA group was significantly lower than that in the placebo group (P <.05) and it remained significantly lower at 12 (P <.001), 18 (P <.001), and 24 (P <.016) months. The rate of PCO in the MDX-RA group was approximately 6 times lower than that in the placebo group (P <.0004). Fifty-seven percent in the placebo group and 4% in the MDX-RA group were projected to require an Nd:YAG capsulotomy within 3 years of primary cataract surgery. Projected values for the placebo group were similar to actual values observed in the population-based cohort. Conclusions: This technique could be used to predict the need for Nd:YAG capsulotomy using early measurements of PCO.
引用
收藏
页码:1621 / 1625
页数:5
相关论文
共 12 条
[1]  
Aron-Rosa D, 1980, AM INTRAOCULAR IMPLA, V6, P352, DOI [10.1016/S0146-2776(80)80036-X, DOI 10.1016/S0146-2776(80)80036-X]
[2]   Inhibition of posterior capsule opacification with an immunotoxin specific for lens epithelial cells: 24 month clinical results [J].
Clark, DS ;
Emery, JM ;
Munsell, MF .
JOURNAL OF CATARACT AND REFRACTIVE SURGERY, 1998, 24 (12) :1614-1620
[3]   Thapsigargin-coated intraocular lenses inhibit human lens cell growth [J].
Duncan, G ;
Wormstone, IM ;
Liu, CSC ;
Marcantonio, JM ;
Davies, PD .
NATURE MEDICINE, 1997, 3 (09) :1026-1028
[4]  
GREEN WR, 1985, T OPHTHAL SOC UK, V104, P727
[5]  
KANSKI JJ, 1989, CLIN OPHTHALMOLOGY S, P252
[6]  
Liu CSC, 1996, INVEST OPHTH VIS SCI, V37, P906
[7]   Heparin eyedrops to prevent posterior capsule opacification [J].
Mastropasqua, L ;
Lobefalo, L ;
Ciancaglini, M ;
Ballone, E ;
Gallenga, PE .
JOURNAL OF CATARACT AND REFRACTIVE SURGERY, 1997, 23 (03) :440-446
[8]  
Murrill C A, 1995, Optom Clin, V4, P69
[9]   EFFECTS OF DICLOFENAC SODIUM AND INDOMETHACIN ON PROLIFERATION AND COLLAGEN-SYNTHESIS OF LENS EPITHELIAL-CELLS IN-VITRO [J].
NISHI, O ;
NISHI, K ;
FUJIWARA, T ;
SHIRASAWA, E .
JOURNAL OF CATARACT AND REFRACTIVE SURGERY, 1995, 21 (04) :461-465
[10]   Inhibition of cell proliferation on lens capsules by 4197X-ricin A immunoconjugate [J].
Tarsio, JF ;
Kelleher, PJ ;
Tarsio, M ;
Emery, JM ;
Lam, DMK .
JOURNAL OF CATARACT AND REFRACTIVE SURGERY, 1997, 23 (02) :260-266